Spaces:
Running
Running
File size: 61,098 Bytes
9754890 |
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285 286 287 288 289 290 291 292 293 294 295 296 297 298 299 300 301 302 303 304 305 306 307 308 309 310 311 312 313 314 315 316 317 318 319 320 321 322 323 324 325 326 327 328 329 330 331 332 333 334 335 336 337 338 339 340 341 342 343 344 345 346 347 348 349 350 351 352 353 354 355 356 357 358 359 360 361 362 363 364 365 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 407 408 409 410 411 412 413 414 415 416 417 418 419 420 421 422 423 424 425 426 427 428 429 430 431 432 433 434 435 436 437 438 439 440 441 442 443 444 445 446 447 448 449 450 451 452 453 454 455 456 457 458 459 460 461 462 463 464 465 466 467 468 469 470 471 472 473 474 475 476 477 478 479 480 481 482 483 484 485 486 487 488 489 490 491 492 493 494 495 496 497 498 499 500 501 502 503 504 505 506 507 508 509 510 511 512 513 514 515 516 517 518 519 520 521 522 523 524 525 526 527 528 529 530 531 532 533 534 535 536 537 538 539 540 541 542 543 544 545 546 547 548 549 550 551 552 553 554 555 556 557 558 559 560 561 562 563 564 565 566 567 568 569 570 571 572 573 574 575 576 577 578 579 580 581 582 583 584 585 586 587 588 589 590 591 592 593 594 595 596 597 598 599 600 601 602 603 604 605 606 607 608 609 610 611 612 613 614 615 616 617 618 619 620 621 622 623 624 625 626 627 628 629 630 631 632 633 634 635 636 637 638 639 640 641 642 643 644 645 646 647 648 649 650 651 652 653 654 655 656 657 658 659 660 661 662 663 664 665 666 667 668 669 670 671 672 673 674 675 676 677 678 679 680 681 682 683 684 685 686 687 688 689 690 691 692 693 694 695 696 697 698 699 700 701 702 703 704 705 706 707 708 709 710 711 712 713 714 715 716 717 718 719 720 721 722 723 724 725 726 727 728 729 730 731 732 733 734 735 736 737 738 739 740 741 742 743 744 745 746 747 748 749 750 751 752 753 754 755 756 757 758 759 760 761 762 763 764 765 766 767 768 769 770 771 772 773 774 775 776 777 778 779 780 781 782 783 784 785 786 787 788 789 790 791 792 793 794 795 796 797 798 799 800 801 802 803 804 805 806 807 808 809 810 811 812 813 814 815 816 817 818 819 820 821 822 823 824 825 826 827 828 829 830 831 832 833 834 835 836 837 838 839 840 841 842 843 844 845 846 847 848 849 850 851 852 853 854 855 856 857 858 859 860 861 862 863 864 865 866 867 868 869 870 871 872 873 874 875 876 877 878 879 880 881 882 883 884 885 886 887 888 889 890 891 892 893 894 895 896 897 898 899 900 901 902 903 904 905 906 907 908 909 910 911 912 913 914 915 916 917 918 919 920 921 922 923 924 925 926 927 928 929 930 931 932 933 934 935 936 937 938 939 940 941 942 943 944 945 946 947 948 949 950 951 952 953 954 955 956 957 958 959 960 961 962 963 964 965 966 967 968 969 970 971 972 973 974 975 976 977 978 979 980 981 982 983 984 985 986 987 988 989 990 991 992 993 994 995 996 997 998 999 1000 1001 1002 1003 1004 1005 1006 1007 1008 1009 1010 1011 1012 1013 1014 1015 1016 1017 1018 1019 1020 1021 1022 1023 1024 1025 1026 1027 1028 1029 1030 1031 1032 1033 1034 1035 1036 1037 1038 1039 1040 1041 1042 1043 1044 1045 1046 1047 1048 1049 1050 1051 1052 1053 1054 1055 1056 1057 1058 1059 1060 1061 1062 |
{
"cells": [
{
"cell_type": "code",
"execution_count": 1,
"metadata": {},
"outputs": [],
"source": [
"import pandas as pd\n",
"from OpenAITools.JRCTTools import fetch_clinical_trials, extract_jrct_links, create_dataframe_from_urls, reorder_columns"
]
},
{
"cell_type": "code",
"execution_count": 2,
"metadata": {},
"outputs": [
{
"name": "stdout",
"output_type": "stream",
"text": [
"検索ボタンがクリックできないため、JavaScriptでクリックします。\n",
"ページネーションが存在しません。全ての結果を取得しました。\n"
]
}
],
"source": [
"# fetch_clinical_trialsを使って検索結果を取得\n",
"results = fetch_clinical_trials(disease_name=\"肉腫\", freeword=\"\",include_not_yet_recruiting=True)"
]
},
{
"cell_type": "code",
"execution_count": 3,
"metadata": {},
"outputs": [
{
"data": {
"text/plain": [
"['初発の小児・AYA世代の肝悪性腫瘍（肝芽腫、HCN-NOS、肝細胞癌、肝内胆管癌、肝未分化肉腫など）',\n",
" '切除不能皮膚血管肉腫',\n",
" '軟部肉腫',\n",
" '未治療又は1レジメンの全身治療歴を有するIDH1変異陽性の局所進行又は転移性の通常型軟骨肉腫',\n",
" '標準治療がない又は不応若しくは不耐の進行再発と診断されたユーイング肉腫又は固形がん',\n",
" '後腹膜原発性高リスク脱分化型脂肪肉腫または平滑筋肉腫',\n",
" '標準治療がない又は不応若しくは不耐の進行再発と診断されたユーイング肉腫又は固形がん',\n",
" '皮膚血管肉腫',\n",
" '後腹膜脱分化型脂肪肉腫',\n",
" '骨軟部肉腫',\n",
" '切除可能高悪性度非円形細胞軟部肉腫',\n",
" '・肉腫、ユーイング 、・新生物転移',\n",
" '高悪性骨肉腫',\n",
" '標準治療不応・不耐もしくは再発又は進行HER2陽性骨・軟部肉腫および婦人科悪性腫瘍',\n",
" '【コホートA】BRCA変異陽性の子宮平滑筋肉腫：募集中\\n【コホートB】BRCA変異陰性・HRD陽性の子宮平滑筋...',\n",
" '横紋筋肉腫',\n",
" '横紋筋肉腫',\n",
" 'ユーイング肉腫ファミリー腫瘍',\n",
" '進行骨軟部肉腫',\n",
" '悪性骨軟部腫瘍（骨軟部肉腫）',\n",
" '頭蓋底脊索腫・軟骨肉腫']"
]
},
"execution_count": 3,
"metadata": {},
"output_type": "execute_result"
}
],
"source": [
"[result[2] for result in results]"
]
},
{
"cell_type": "code",
"execution_count": 4,
"metadata": {},
"outputs": [
{
"name": "stdout",
"output_type": "stream",
"text": [
"Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT1060240085\n",
"Waiting for 5 seconds before the next request...\n",
"Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2031240448\n",
"Waiting for 5 seconds before the next request...\n",
"Processing URL: https://jrct.niph.go.jp/latest-detail/jRCTs061240064\n",
"Waiting for 5 seconds before the next request...\n",
"Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2061240032\n",
"Waiting for 5 seconds before the next request...\n",
"Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT1030240137\n",
"Waiting for 5 seconds before the next request...\n",
"Processing URL: https://jrct.niph.go.jp/latest-detail/jRCTs031230482\n",
"Waiting for 5 seconds before the next request...\n",
"Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2033230299\n",
"Waiting for 5 seconds before the next request...\n",
"Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2021230016\n",
"Waiting for 5 seconds before the next request...\n",
"Processing URL: https://jrct.niph.go.jp/latest-detail/jRCTs041230007\n",
"Waiting for 5 seconds before the next request...\n",
"Processing URL: https://jrct.niph.go.jp/latest-detail/jRCTs032220609\n",
"Waiting for 5 seconds before the next request...\n",
"Processing URL: https://jrct.niph.go.jp/latest-detail/jRCTs031220446\n",
"Waiting for 5 seconds before the next request...\n",
"Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2071220043\n",
"Waiting for 5 seconds before the next request...\n",
"Processing URL: https://jrct.niph.go.jp/latest-detail/jRCTs041220024\n",
"Waiting for 5 seconds before the next request...\n",
"Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2033220088\n",
"Waiting for 5 seconds before the next request...\n",
"Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2031210264\n",
"Waiting for 5 seconds before the next request...\n",
"Processing URL: https://jrct.niph.go.jp/latest-detail/jRCTs051180207\n",
"Waiting for 5 seconds before the next request...\n",
"Processing URL: https://jrct.niph.go.jp/latest-detail/jRCTs051180200\n",
"Waiting for 5 seconds before the next request...\n",
"Processing URL: https://jrct.niph.go.jp/latest-detail/jRCTs021180022\n",
"Waiting for 5 seconds before the next request...\n",
"Processing URL: https://jrct.niph.go.jp/latest-detail/jRCTs051180042\n",
"Waiting for 5 seconds before the next request...\n",
"Processing URL: https://jrct.niph.go.jp/latest-detail/jRCTs052180038\n",
"Waiting for 5 seconds before the next request...\n",
"Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT1032180086\n",
"Waiting for 5 seconds before the next request...\n"
]
}
],
"source": [
" # jRCT詳細リンクを作成\n",
"jrct_links = extract_jrct_links(results)\n",
"\n",
" # 詳細リンクからデータフレームを作成\n",
"df = create_dataframe_from_urls(jrct_links,delay=5)"
]
},
{
"cell_type": "code",
"execution_count": 6,
"metadata": {},
"outputs": [],
"source": [
"# 整列後の DataFrame を作成\n",
"sorted_df = reorder_columns(df)"
]
},
{
"cell_type": "code",
"execution_count": 7,
"metadata": {},
"outputs": [
{
"name": "stderr",
"output_type": "stream",
"text": [
"/var/folders/xj/t9whz9_x5g309fn84ql50wrm0000gn/T/ipykernel_93066/3932068550.py:1: SettingWithCopyWarning: \n",
"A value is trying to be set on a copy of a slice from a DataFrame.\n",
"Try using .loc[row_indexer,col_indexer] = value instead\n",
"\n",
"See the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n",
" sorted_df['JRCT ID'] = [result[0] for result in results]\n",
"/var/folders/xj/t9whz9_x5g309fn84ql50wrm0000gn/T/ipykernel_93066/3932068550.py:2: SettingWithCopyWarning: \n",
"A value is trying to be set on a copy of a slice from a DataFrame.\n",
"Try using .loc[row_indexer,col_indexer] = value instead\n",
"\n",
"See the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n",
" sorted_df['Title'] = [result[1] for result in results]\n",
"/var/folders/xj/t9whz9_x5g309fn84ql50wrm0000gn/T/ipykernel_93066/3932068550.py:3: SettingWithCopyWarning: \n",
"A value is trying to be set on a copy of a slice from a DataFrame.\n",
"Try using .loc[row_indexer,col_indexer] = value instead\n",
"\n",
"See the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n",
" sorted_df['Target'] = [result[2] for result in results]\n"
]
}
],
"source": [
"sorted_df['JRCT ID'] = [result[0] for result in results]\n",
"sorted_df['Title'] = [result[1] for result in results]\n",
"sorted_df['Target'] = [result[2] for result in results]"
]
},
{
"cell_type": "code",
"execution_count": 8,
"metadata": {},
"outputs": [],
"source": [
"new_order = [\"JRCT ID\", \"Title\",'Target'] + [col for col in sorted_df.columns if col not in [\"JRCT ID\", \"Title\",'Target']]"
]
},
{
"cell_type": "code",
"execution_count": 9,
"metadata": {},
"outputs": [],
"source": [
"sorted_df = sorted_df[new_order]"
]
},
{
"cell_type": "code",
"execution_count": 10,
"metadata": {},
"outputs": [
{
"data": {
"text/html": [
"<div>\n",
"<style scoped>\n",
" .dataframe tbody tr th:only-of-type {\n",
" vertical-align: middle;\n",
" }\n",
"\n",
" .dataframe tbody tr th {\n",
" vertical-align: top;\n",
" }\n",
"\n",
" .dataframe thead th {\n",
" text-align: right;\n",
" }\n",
"</style>\n",
"<table border=\"1\" class=\"dataframe\">\n",
" <thead>\n",
" <tr style=\"text-align: right;\">\n",
" <th></th>\n",
" <th>JRCT ID</th>\n",
" <th>Title</th>\n",
" <th>Target</th>\n",
" <th>研究・治験の目的</th>\n",
" <th>試験の種類</th>\n",
" <th>無作為化</th>\n",
" <th>盲検化</th>\n",
" <th>対照</th>\n",
" <th>割付け</th>\n",
" <th>研究目的</th>\n",
" <th>...</th>\n",
" <th>Inclusion Criteria</th>\n",
" <th>Exclusion Criteria</th>\n",
" <th>Age Minimum</th>\n",
" <th>Age Maximum</th>\n",
" <th>Gender</th>\n",
" <th>Discontinuation Criteria</th>\n",
" <th>Keyword</th>\n",
" <th>Intervention(s)</th>\n",
" <th>Phase</th>\n",
" <th>Target</th>\n",
" </tr>\n",
" </thead>\n",
" <tbody>\n",
" <tr>\n",
" <th>0</th>\n",
" <td>jRCT1060240085</td>\n",
" <td>小児およびAYA肝腫瘍における術前３Ｄシミュレーションとそれに基づく術式立案システムの実行可...</td>\n",
" <td>初発の小児・AYA世代の肝悪性腫瘍（肝芽腫、HCN-NOS、肝細胞癌、肝内胆管癌、肝未分化肉...</td>\n",
" <td>本研究の目的は、小児・AYA肝腫瘍を対象として現在おこなっている中央画像診断、中央病理診断に...</td>\n",
" <td>観察研究</td>\n",
" <td>単一群</td>\n",
" <td>非盲検</td>\n",
" <td>非対照</td>\n",
" <td>単群比較</td>\n",
" <td>治療</td>\n",
" <td>...</td>\n",
" <td>1. Diagnosed or suspected to have a non-treate...</td>\n",
" <td>If the research director or co-researchers det...</td>\n",
" <td>No limit</td>\n",
" <td>40age old not</td>\n",
" <td></td>\n",
" <td>None</td>\n",
" <td>hepatoblastoma, HCN-NOS, hepatocellular carcin...</td>\n",
" <td></td>\n",
" <td>NaN</td>\n",
" <td>初発の小児・AYA世代の肝悪性腫瘍（肝芽腫、HCN-NOS、肝細胞癌、肝内胆管癌、肝未分化肉...</td>\n",
" </tr>\n",
" <tr>\n",
" <th>1</th>\n",
" <td>jRCT2031240448</td>\n",
" <td>切除不能皮膚血管肉腫に対するペムブロリズマブ＋レンバチニブ併用療法の第II相医師主導治験</td>\n",
" <td>切除不能皮膚血管肉腫</td>\n",
" <td>切除不能皮膚血管肉腫に対するペムブロリズマブ＋レンバチニブ併用療法の有効性を検証し、有効性と...</td>\n",
" <td>NaN</td>\n",
" <td>単一群</td>\n",
" <td>非盲検</td>\n",
" <td>非対照</td>\n",
" <td>単群比較</td>\n",
" <td>治療</td>\n",
" <td>...</td>\n",
" <td>1)\\tHistologically diagnosed with cutaneous an...</td>\n",
" <td>1)\\tPatients previously treated with anti-PD-1...</td>\n",
" <td>18age old over</td>\n",
" <td>85age old under</td>\n",
" <td>Both</td>\n",
" <td>None</td>\n",
" <td>cutaneous angiosarcoma, angiosarcoma</td>\n",
" <td>Each course is set at 21 days. Pembrolizumab 2...</td>\n",
" <td>NaN</td>\n",
" <td>切除不能皮膚血管肉腫</td>\n",
" </tr>\n",
" <tr>\n",
" <th>2</th>\n",
" <td>jRCTs061240064</td>\n",
" <td>進行期悪性軟部腫瘍に対するドキソルビシン及びトラベクテジン併用療法の有効性に関する非対照研究</td>\n",
" <td>軟部肉腫</td>\n",
" <td>進行期軟部肉腫患者に対するドキソルビシンとトラベクテジン併用療法の有効性を無増悪生存期間，疾...</td>\n",
" <td>介入研究</td>\n",
" <td>単一群</td>\n",
" <td>非盲検</td>\n",
" <td>ヒストリカルコントロール</td>\n",
" <td>単群比較</td>\n",
" <td>治療</td>\n",
" <td>...</td>\n",
" <td>1. Patients with pathologically diagnosed mali...</td>\n",
" <td>1. Patients who have received a cumulative dos...</td>\n",
" <td>18age old exceed</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>None</td>\n",
" <td>Soft tissue sarcoma</td>\n",
" <td>Doxorubicin (60 mg/m2) for 15 minutes, Trabect...</td>\n",
" <td>NaN</td>\n",
" <td>軟部肉腫</td>\n",
" </tr>\n",
" <tr>\n",
" <th>3</th>\n",
" <td>jRCT2061240032</td>\n",
" <td>18歳以上の未治療又は1レジメンの全身治療歴を有するIDH1変異陽性の局所進行又は転移性の通...</td>\n",
" <td>未治療又は1レジメンの全身治療歴を有するIDH1変異陽性の局所進行又は転移性の通常型軟骨肉腫</td>\n",
" <td>Grade 1及びGrade 2の患者を対象に盲検化独立中央判定者（BICR）による腫瘍評価...</td>\n",
" <td>NaN</td>\n",
" <td>無作為化比較</td>\n",
" <td>二重盲検</td>\n",
" <td>プラセボ対照</td>\n",
" <td>並行群間比較</td>\n",
" <td>治療</td>\n",
" <td>...</td>\n",
" <td>Have a histopathological diagnosis (fresh or b...</td>\n",
" <td>Are unable to swallow oral medication.\\n\\r\\nPr...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>None</td>\n",
" <td>Chondrosarcoma</td>\n",
" <td>Drug: Ivosidenib 500mg or Placebo\\n\\r\\nProvide...</td>\n",
" <td>NaN</td>\n",
" <td>未治療又は1レジメンの全身治療歴を有するIDH1変異陽性の局所進行又は転移性の通常型軟骨肉腫</td>\n",
" </tr>\n",
" <tr>\n",
" <th>4</th>\n",
" <td>jRCT1030240137</td>\n",
" <td>EPHB4受容体発現のユーイング肉腫又は固形がんを対象とした非ウイルス遺伝子改変CAR-T細...</td>\n",
" <td>標準治療がない又は不応若しくは不耐の進行再発と診断されたユーイング肉腫又は固形がん</td>\n",
" <td>CARTiEr試験において、AP8901が投与された被検者におけるヒト体内での動態ならびに作...</td>\n",
" <td>観察研究</td>\n",
" <td>単一群</td>\n",
" <td>非盲検</td>\n",
" <td>非対照</td>\n",
" <td>単群比較</td>\n",
" <td>治療</td>\n",
" <td>...</td>\n",
" <td>1.Patients enrolled in CARTiEr study\\n\\r\\n2.Wr...</td>\n",
" <td>1.Written consent has not been obtained from t...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>None</td>\n",
" <td></td>\n",
" <td></td>\n",
" <td>NaN</td>\n",
" <td>標準治療がない又は不応若しくは不耐の進行再発と診断されたユーイング肉腫又は固形がん</td>\n",
" </tr>\n",
" <tr>\n",
" <th>5</th>\n",
" <td>jRCTs031230482</td>\n",
" <td>JCOG2214INT: 高リスク後腹膜肉腫に対する術前補助化学療法の意義に関するランダム化...</td>\n",
" <td>後腹膜原発性高リスク脱分化型脂肪肉腫または平滑筋肉腫</td>\n",
" <td>切除可能な後腹膜発生高リスク脱分化型脂肪肉腫および平滑筋肉腫を対象に、標準治療である根治的手...</td>\n",
" <td>介入研究</td>\n",
" <td>無作為化比較</td>\n",
" <td>非盲検</td>\n",
" <td>実薬（治療）対照</td>\n",
" <td>並行群間比較</td>\n",
" <td>治療</td>\n",
" <td>...</td>\n",
" <td>* Histologically proven primary high risk leio...</td>\n",
" <td>* Sarcoma originating from bone structure, abd...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>None</td>\n",
" <td></td>\n",
" <td>Patients in the standard arm (surgery alone) w...</td>\n",
" <td>NaN</td>\n",
" <td>後腹膜原発性高リスク脱分化型脂肪肉腫または平滑筋肉腫</td>\n",
" </tr>\n",
" <tr>\n",
" <th>6</th>\n",
" <td>jRCT2033230299</td>\n",
" <td>EPHB4受容体発現のユーイング肉腫又は固形がんを対象とした非ウイルス遺伝子改変CAR-T細...</td>\n",
" <td>標準治療がない又は不応若しくは不耐の進行再発と診断されたユーイング肉腫又は固形がん</td>\n",
" <td>転移・再発に対して標準治療がない又は不応若しくは不耐の EPHB4 受容体を発現するユーイン...</td>\n",
" <td>NaN</td>\n",
" <td>単一群</td>\n",
" <td>非盲検</td>\n",
" <td>非対照</td>\n",
" <td>単群比較</td>\n",
" <td>治療</td>\n",
" <td>...</td>\n",
" <td>1.Patients who have voluntarily provided writt...</td>\n",
" <td>1.Patients with other malignancies or history ...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>None</td>\n",
" <td></td>\n",
" <td>Administration of CAR-T cells produced from er...</td>\n",
" <td>NaN</td>\n",
" <td>標準治療がない又は不応若しくは不耐の進行再発と診断されたユーイング肉腫又は固形がん</td>\n",
" </tr>\n",
" <tr>\n",
" <th>7</th>\n",
" <td>jRCT2021230016</td>\n",
" <td>皮膚血管肉腫に対するパクリタキセルとTM5614併用の安全性・有効性を検討する第Ⅱ相医師主導治験</td>\n",
" <td>皮膚血管肉腫</td>\n",
" <td>皮膚血管肉腫のパクリタキセル単剤療法無効症例を対象にTM5614とパクリタキセルの併用時にお...</td>\n",
" <td>NaN</td>\n",
" <td>単一群</td>\n",
" <td>非盲検</td>\n",
" <td>非対照</td>\n",
" <td>単群比較</td>\n",
" <td>治療</td>\n",
" <td>...</td>\n",
" <td>(1) Patients who are 18 years old over (at the...</td>\n",
" <td>(1) Patients with concomitant or pre-existing ...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>None</td>\n",
" <td></td>\n",
" <td>(TM5614)\\n\\r\\nTM5614 should be taken orally af...</td>\n",
" <td>NaN</td>\n",
" <td>皮膚血管肉腫</td>\n",
" </tr>\n",
" <tr>\n",
" <th>8</th>\n",
" <td>jRCTs041230007</td>\n",
" <td>後腹膜脱分化型脂肪肉腫に対する術前AI（ドキソルビシン・イホスファミド）療法の単群第Ⅱ相試験</td>\n",
" <td>後腹膜脱分化型脂肪肉腫</td>\n",
" <td>肉眼的根治切除をし得た後腹膜脱分化型脂肪肉腫患者の術前ドキソルビシン・イホスファミド療法の有...</td>\n",
" <td>介入研究</td>\n",
" <td>単一群</td>\n",
" <td>非盲検</td>\n",
" <td>非対照</td>\n",
" <td>単群比較</td>\n",
" <td>治療</td>\n",
" <td>...</td>\n",
" <td>The patients diagnosed with de-differentiated ...</td>\n",
" <td>The patients have a severe allergy and drug hy...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>None</td>\n",
" <td>retroperitoneal de-differentiated liposarcoma</td>\n",
" <td>Doxorubicin (20mg/m2/day), IV, given on day1-3...</td>\n",
" <td>NaN</td>\n",
" <td>後腹膜脱分化型脂肪肉腫</td>\n",
" </tr>\n",
" <tr>\n",
" <th>9</th>\n",
" <td>jRCTs032220609</td>\n",
" <td>骨軟部肉腫に対する線量平均LET最適化マルチイオン重粒子線治療のFeasibility臨床研究</td>\n",
" <td>骨軟部肉腫</td>\n",
" <td>骨軟部肉腫に対して既存の重粒子線治療法の生物線量を維持しつつ、腫瘍内の線量平均LET値の最適...</td>\n",
" <td>介入研究</td>\n",
" <td>単一群</td>\n",
" <td>非盲検</td>\n",
" <td>非対照</td>\n",
" <td>単群比較</td>\n",
" <td>治療</td>\n",
" <td>...</td>\n",
" <td>1. Histologically diagnosed high-grade bone an...</td>\n",
" <td>1.\\tPatients with serious complications.\\n\\r\\n...</td>\n",
" <td>No limit</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>None</td>\n",
" <td>sarcoma</td>\n",
" <td>Multi-ion radiotherapy</td>\n",
" <td>NaN</td>\n",
" <td>骨軟部肉腫</td>\n",
" </tr>\n",
" <tr>\n",
" <th>10</th>\n",
" <td>jRCTs031220446</td>\n",
" <td>JCOG2102: 切除可能高悪性度非円形細胞軟部肉腫に対する術前術後補助化学療法と術後補助...</td>\n",
" <td>切除可能高悪性度非円形細胞軟部肉腫</td>\n",
" <td>切除可能なStage IIIA/B（T2-4N0M0）の非円形細胞軟部肉腫を対象に、標準治療...</td>\n",
" <td>介入研究</td>\n",
" <td>無作為化比較</td>\n",
" <td>非盲検</td>\n",
" <td>実薬（治療）対照</td>\n",
" <td>並行群間比較</td>\n",
" <td>治療</td>\n",
" <td>...</td>\n",
" <td>(1) Grade 2 or 3 (FNCLCC histological grading ...</td>\n",
" <td>(1) Synchronous or metachronous (within 5 year...</td>\n",
" <td>16age old over</td>\n",
" <td>70age old under</td>\n",
" <td>Both</td>\n",
" <td>None</td>\n",
" <td></td>\n",
" <td>Arm A: Three courses of preoperative chemother...</td>\n",
" <td>NaN</td>\n",
" <td>切除可能高悪性度非円形細胞軟部肉腫</td>\n",
" </tr>\n",
" <tr>\n",
" <th>11</th>\n",
" <td>jRCT2071220043</td>\n",
" <td>再発又は難治性ユーイング肉腫を有する患者を対象に、イリノテカン及びテモゾロミドと併用したとき...</td>\n",
" <td>・肉腫、ユーイング 、・新生物転移</td>\n",
" <td>CAMPFIRE：ユーイング肉腫患者を対象としたアベマシクリブ（LY2835219)の研究</td>\n",
" <td>NaN</td>\n",
" <td>無作為化比較</td>\n",
" <td>非盲検</td>\n",
" <td>実薬（治療）対照</td>\n",
" <td>並行群間比較</td>\n",
" <td>治療</td>\n",
" <td>...</td>\n",
" <td>-Diagnosis of Ewing's sarcoma or Ewing's sarco...</td>\n",
" <td>-Participants with severe and/or uncontrolled ...</td>\n",
" <td>1age old over</td>\n",
" <td>39age old under</td>\n",
" <td>Both</td>\n",
" <td>None</td>\n",
" <td></td>\n",
" <td>-Drug: Abemaciclib\\n\\r\\n Orally\\n\\r\\n Ot...</td>\n",
" <td>NaN</td>\n",
" <td>・肉腫、ユーイング 、・新生物転移</td>\n",
" </tr>\n",
" <tr>\n",
" <th>12</th>\n",
" <td>jRCTs041220024</td>\n",
" <td>高悪性骨肉腫を対象としたメトトレキサート・アドリアマイシン・シスプラチン（MAP）療法にがん...</td>\n",
" <td>高悪性骨肉腫</td>\n",
" <td>臨床病期ⅡA、ⅡB、Ⅲ期、Ⅳ期又は術後再発の高悪性骨肉腫患者に対してファスジル＋MAP療法（...</td>\n",
" <td>介入研究</td>\n",
" <td>単一群</td>\n",
" <td>非盲検</td>\n",
" <td>非対照</td>\n",
" <td>単群比較</td>\n",
" <td>治療</td>\n",
" <td>...</td>\n",
" <td>1.\\tStage2A, 2B, 3,4, or recurrent high grade ...</td>\n",
" <td>1.\\tLatest adequate organ function as proved b...</td>\n",
" <td>14age old over</td>\n",
" <td>65age old not</td>\n",
" <td>Both</td>\n",
" <td>None</td>\n",
" <td></td>\n",
" <td>fasudil hydrochloride hydrate as an IV infusion</td>\n",
" <td>NaN</td>\n",
" <td>高悪性骨肉腫</td>\n",
" </tr>\n",
" <tr>\n",
" <th>13</th>\n",
" <td>jRCT2033220088</td>\n",
" <td>HER2特異的キメラ抗原受容体（CAR）遺伝子改変T細胞療法の安全性に関する臨床第Ⅰ相試験</td>\n",
" <td>標準治療不応・不耐もしくは再発又は進行HER2陽性骨・軟部肉腫および婦人科悪性腫瘍</td>\n",
" <td>標準治療により不応・不耐もしくは再発又は進行HER2陽性骨・軟部肉腫および婦人科悪性腫瘍患者...</td>\n",
" <td>NaN</td>\n",
" <td>単一群</td>\n",
" <td>非盲検</td>\n",
" <td>非対照</td>\n",
" <td>単群比較</td>\n",
" <td>治療</td>\n",
" <td>...</td>\n",
" <td>SC1 (before apheresis)\\n\\r\\n1. Patients diagno...</td>\n",
" <td>SC1 (pre-apheresis), SC2 (pre-treatment initia...</td>\n",
" <td>5age old over</td>\n",
" <td>65age old not</td>\n",
" <td>Both</td>\n",
" <td>None</td>\n",
" <td></td>\n",
" <td>Administration of CAR-T cells produced from er...</td>\n",
" <td>NaN</td>\n",
" <td>標準治療不応・不耐もしくは再発又は進行HER2陽性骨・軟部肉腫および婦人科悪性腫瘍</td>\n",
" </tr>\n",
" <tr>\n",
" <th>14</th>\n",
" <td>jRCT2031210264</td>\n",
" <td>HRD陽性再発・難治性婦人科希少がんに対するNiraparibの安全性・有効性を評価する単群...</td>\n",
" <td>【コホートA】BRCA変異陽性の子宮平滑筋肉腫：募集中\\n【コホートB】BRCA変異陰性・H...</td>\n",
" <td>HRD陽性再発・難治性婦人科希少がんに対するNiraparibの安全性・有効性を評価する。</td>\n",
" <td>NaN</td>\n",
" <td>単一群</td>\n",
" <td>非盲検</td>\n",
" <td>非対照</td>\n",
" <td>単群比較</td>\n",
" <td>治療</td>\n",
" <td>...</td>\n",
" <td>Patients who meet all of the following criteri...</td>\n",
" <td>Subject will be excluded from the trial if the...</td>\n",
" <td>20age old over</td>\n",
" <td>No limit</td>\n",
" <td>Female</td>\n",
" <td>None</td>\n",
" <td>gynecology, malignancy, rare, gynecologic rare...</td>\n",
" <td>A 200 mg dose of niraparib is orally administe...</td>\n",
" <td>NaN</td>\n",
" <td>【コホートA】BRCA変異陽性の子宮平滑筋肉腫：募集中\\n【コホートB】BRCA変異陰性・H...</td>\n",
" </tr>\n",
" <tr>\n",
" <th>15</th>\n",
" <td>jRCTs051180207</td>\n",
" <td>横紋筋肉腫中間リスク群患者に対するVAC2.2（ビンクリスチン、アクチノマイシンD、シクロホ...</td>\n",
" <td>横紋筋肉腫</td>\n",
" <td>Stage 2、3、Group IIIに分類される胎児型横紋筋肉腫、Group I, II、...</td>\n",
" <td>介入研究</td>\n",
" <td>単一群</td>\n",
" <td>非盲検</td>\n",
" <td>無治療対照/標準治療対照</td>\n",
" <td>単群比較</td>\n",
" <td>治療</td>\n",
" <td>...</td>\n",
" <td>1) Histologically confirmed newly diagnosed rh...</td>\n",
" <td>1) patients with synchronous or metachronous c...</td>\n",
" <td>1age old over</td>\n",
" <td>29age old under</td>\n",
" <td>Both</td>\n",
" <td>None</td>\n",
" <td>Rhabdomyosarcoma</td>\n",
" <td>chemotherapy 43 weeks \\n\\r\\nVAC2.2 therapy 9 c...</td>\n",
" <td>NaN</td>\n",
" <td>横紋筋肉腫</td>\n",
" </tr>\n",
" <tr>\n",
" <th>16</th>\n",
" <td>jRCTs051180200</td>\n",
" <td>横紋筋肉腫低リスクB群患者に対するVAC1.2（ビンクリスチン、アクチノマイシンD、シクロホ...</td>\n",
" <td>横紋筋肉腫</td>\n",
" <td>Stage 1、 Group III（眼窩Group III N0、NXを除く）、または、S...</td>\n",
" <td>介入研究</td>\n",
" <td>単一群</td>\n",
" <td>非盲検</td>\n",
" <td>非対照</td>\n",
" <td>単群比較</td>\n",
" <td>治療</td>\n",
" <td>...</td>\n",
" <td>1) Histologically confirmed newly diagnosed em...</td>\n",
" <td>1) patients with primary tumor of CNS origin, ...</td>\n",
" <td>No limit</td>\n",
" <td>29age old under</td>\n",
" <td>Both</td>\n",
" <td>None</td>\n",
" <td>rhabdomyosarcoma</td>\n",
" <td>chemotherapy 43 weeks \\n\\r\\nVAC1.2 therapy 9 c...</td>\n",
" <td>NaN</td>\n",
" <td>横紋筋肉腫</td>\n",
" </tr>\n",
" <tr>\n",
" <th>17</th>\n",
" <td>jRCTs021180022</td>\n",
" <td>限局性ユーイング肉腫ファミリー腫瘍に対するG-CSF併用治療期間短縮VDC-IE療法を用いた...</td>\n",
" <td>ユーイング肉腫ファミリー腫瘍</td>\n",
" <td>新規に診断された限局性ユーイング肉腫ファミリー腫瘍（ESFT）に対して、VDC-IE療法を顆...</td>\n",
" <td>介入研究</td>\n",
" <td>単一群</td>\n",
" <td>非盲検</td>\n",
" <td>非対照</td>\n",
" <td>単群比較</td>\n",
" <td>治療</td>\n",
" <td>...</td>\n",
" <td>1. Histologically confirmed newly diagnosed ES...</td>\n",
" <td>1. Patients with synchronous or metachronous c...</td>\n",
" <td>No limit</td>\n",
" <td>50age 0month old not</td>\n",
" <td>Both</td>\n",
" <td>None</td>\n",
" <td>Ewing sarcoma</td>\n",
" <td>Chemotherapy\\n\\r\\nStandard therapy for localiz...</td>\n",
" <td>NaN</td>\n",
" <td>ユーイング肉腫ファミリー腫瘍</td>\n",
" </tr>\n",
" <tr>\n",
" <th>18</th>\n",
" <td>jRCTs051180042</td>\n",
" <td>進行骨軟部肉腫に対するゲムシタビン/ドセタキセル併用療法の第Ⅱ相臨床試験</td>\n",
" <td>進行骨軟部肉腫</td>\n",
" <td>本試験は、再発または遠隔転移を有する進行骨軟部肉腫に対するゲムシタビン/ドセタキセル併用療法...</td>\n",
" <td>介入研究</td>\n",
" <td>単一群</td>\n",
" <td>非盲検</td>\n",
" <td>非対照</td>\n",
" <td>単群比較</td>\n",
" <td>治療</td>\n",
" <td>...</td>\n",
" <td>1)Patients are histopathologically diagnosed a...</td>\n",
" <td>1)Active double cancers within 5 years(cured i...</td>\n",
" <td>10age 0month 0week old over</td>\n",
" <td>70age 11month 4week old under</td>\n",
" <td>Both</td>\n",
" <td>None</td>\n",
" <td></td>\n",
" <td>Gemcitabine (900 mg/m2) intravenously(IV) on D...</td>\n",
" <td>NaN</td>\n",
" <td>進行骨軟部肉腫</td>\n",
" </tr>\n",
" <tr>\n",
" <th>19</th>\n",
" <td>jRCTs052180038</td>\n",
" <td>炭酸ガス経皮吸収による悪性骨軟部腫瘍に対する安全性および抗腫瘍効果に関する探索的臨床研究</td>\n",
" <td>悪性骨軟部腫瘍（骨軟部肉腫）</td>\n",
" <td>悪性骨軟部腫瘍に対する炭酸ガス経皮吸収の安全性と有用性を評価すること</td>\n",
" <td>介入研究</td>\n",
" <td>単一群</td>\n",
" <td>非盲検</td>\n",
" <td>非対照</td>\n",
" <td>単群比較</td>\n",
" <td>治療</td>\n",
" <td>...</td>\n",
" <td>(1) Patients who have been histologically diag...</td>\n",
" <td>(1) Skin ulcer or pathological fracture in the...</td>\n",
" <td>16age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>None</td>\n",
" <td>sarcoma</td>\n",
" <td>Transcutaneous carbon dioxide (CO2) applicatio...</td>\n",
" <td>NaN</td>\n",
" <td>悪性骨軟部腫瘍（骨軟部肉腫）</td>\n",
" </tr>\n",
" <tr>\n",
" <th>20</th>\n",
" <td>jRCT1032180086</td>\n",
" <td>頭蓋底脊索腫・軟骨肉腫術後に対する陽子線治療の有効性・安全性を評価する第II相試験</td>\n",
" <td>頭蓋底脊索腫・軟骨肉腫</td>\n",
" <td>頭蓋底脊索腫術後に対する陽子線治療の有効性・安全性判定</td>\n",
" <td>介入研究</td>\n",
" <td>単一群</td>\n",
" <td>非盲検</td>\n",
" <td>非対照</td>\n",
" <td>単群比較</td>\n",
" <td>治療</td>\n",
" <td>...</td>\n",
" <td>1, Pathological diagnosis is chordoma or chond...</td>\n",
" <td>1, Multiple primary cancers\\n\\r\\n2, Invasion f...</td>\n",
" <td>15age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>None</td>\n",
" <td>proton radiation therapy, proton beam therapy,...</td>\n",
" <td>Proton Radiation Therapy</td>\n",
" <td>NaN</td>\n",
" <td>頭蓋底脊索腫・軟骨肉腫</td>\n",
" </tr>\n",
" </tbody>\n",
"</table>\n",
"<p>21 rows × 36 columns</p>\n",
"</div>"
],
"text/plain": [
" JRCT ID Title \\\n",
"0 jRCT1060240085 小児およびAYA肝腫瘍における術前３Ｄシミュレーションとそれに基づく術式立案システムの実行可... \n",
"1 jRCT2031240448 切除不能皮膚血管肉腫に対するペムブロリズマブ＋レンバチニブ併用療法の第II相医師主導治験 \n",
"2 jRCTs061240064 進行期悪性軟部腫瘍に対するドキソルビシン及びトラベクテジン併用療法の有効性に関する非対照研究 \n",
"3 jRCT2061240032 18歳以上の未治療又は1レジメンの全身治療歴を有するIDH1変異陽性の局所進行又は転移性の通... \n",
"4 jRCT1030240137 EPHB4受容体発現のユーイング肉腫又は固形がんを対象とした非ウイルス遺伝子改変CAR-T細... \n",
"5 jRCTs031230482 JCOG2214INT: 高リスク後腹膜肉腫に対する術前補助化学療法の意義に関するランダム化... \n",
"6 jRCT2033230299 EPHB4受容体発現のユーイング肉腫又は固形がんを対象とした非ウイルス遺伝子改変CAR-T細... \n",
"7 jRCT2021230016 皮膚血管肉腫に対するパクリタキセルとTM5614併用の安全性・有効性を検討する第Ⅱ相医師主導治験 \n",
"8 jRCTs041230007 後腹膜脱分化型脂肪肉腫に対する術前AI（ドキソルビシン・イホスファミド）療法の単群第Ⅱ相試験 \n",
"9 jRCTs032220609 骨軟部肉腫に対する線量平均LET最適化マルチイオン重粒子線治療のFeasibility臨床研究 \n",
"10 jRCTs031220446 JCOG2102: 切除可能高悪性度非円形細胞軟部肉腫に対する術前術後補助化学療法と術後補助... \n",
"11 jRCT2071220043 再発又は難治性ユーイング肉腫を有する患者を対象に、イリノテカン及びテモゾロミドと併用したとき... \n",
"12 jRCTs041220024 高悪性骨肉腫を対象としたメトトレキサート・アドリアマイシン・シスプラチン（MAP）療法にがん... \n",
"13 jRCT2033220088 HER2特異的キメラ抗原受容体（CAR）遺伝子改変T細胞療法の安全性に関する臨床第Ⅰ相試験 \n",
"14 jRCT2031210264 HRD陽性再発・難治性婦人科希少がんに対するNiraparibの安全性・有効性を評価する単群... \n",
"15 jRCTs051180207 横紋筋肉腫中間リスク群患者に対するVAC2.2（ビンクリスチン、アクチノマイシンD、シクロホ... \n",
"16 jRCTs051180200 横紋筋肉腫低リスクB群患者に対するVAC1.2（ビンクリスチン、アクチノマイシンD、シクロホ... \n",
"17 jRCTs021180022 限局性ユーイング肉腫ファミリー腫瘍に対するG-CSF併用治療期間短縮VDC-IE療法を用いた... \n",
"18 jRCTs051180042 進行骨軟部肉腫に対するゲムシタビン/ドセタキセル併用療法の第Ⅱ相臨床試験 \n",
"19 jRCTs052180038 炭酸ガス経皮吸収による悪性骨軟部腫瘍に対する安全性および抗腫瘍効果に関する探索的臨床研究 \n",
"20 jRCT1032180086 頭蓋底脊索腫・軟骨肉腫術後に対する陽子線治療の有効性・安全性を評価する第II相試験 \n",
"\n",
" Target \\\n",
"0 初発の小児・AYA世代の肝悪性腫瘍（肝芽腫、HCN-NOS、肝細胞癌、肝内胆管癌、肝未分化肉... \n",
"1 切除不能皮膚血管肉腫 \n",
"2 軟部肉腫 \n",
"3 未治療又は1レジメンの全身治療歴を有するIDH1変異陽性の局所進行又は転移性の通常型軟骨肉腫 \n",
"4 標準治療がない又は不応若しくは不耐の進行再発と診断されたユーイング肉腫又は固形がん \n",
"5 後腹膜原発性高リスク脱分化型脂肪肉腫または平滑筋肉腫 \n",
"6 標準治療がない又は不応若しくは不耐の進行再発と診断されたユーイング肉腫又は固形がん \n",
"7 皮膚血管肉腫 \n",
"8 後腹膜脱分化型脂肪肉腫 \n",
"9 骨軟部肉腫 \n",
"10 切除可能高悪性度非円形細胞軟部肉腫 \n",
"11 ・肉腫、ユーイング 、・新生物転移 \n",
"12 高悪性骨肉腫 \n",
"13 標準治療不応・不耐もしくは再発又は進行HER2陽性骨・軟部肉腫および婦人科悪性腫瘍 \n",
"14 【コホートA】BRCA変異陽性の子宮平滑筋肉腫：募集中\\n【コホートB】BRCA変異陰性・H... \n",
"15 横紋筋肉腫 \n",
"16 横紋筋肉腫 \n",
"17 ユーイング肉腫ファミリー腫瘍 \n",
"18 進行骨軟部肉腫 \n",
"19 悪性骨軟部腫瘍（骨軟部肉腫） \n",
"20 頭蓋底脊索腫・軟骨肉腫 \n",
"\n",
" 研究・治験の目的 試験の種類 無作為化 盲検化 \\\n",
"0 本研究の目的は、小児・AYA肝腫瘍を対象として現在おこなっている中央画像診断、中央病理診断に... 観察研究 単一群 非盲検 \n",
"1 切除不能皮膚血管肉腫に対するペムブロリズマブ＋レンバチニブ併用療法の有効性を検証し、有効性と... NaN 単一群 非盲検 \n",
"2 進行期軟部肉腫患者に対するドキソルビシンとトラベクテジン併用療法の有効性を無増悪生存期間，疾... 介入研究 単一群 非盲検 \n",
"3 Grade 1及びGrade 2の患者を対象に盲検化独立中央判定者（BICR）による腫瘍評価... NaN 無作為化比較 二重盲検 \n",
"4 CARTiEr試験において、AP8901が投与された被検者におけるヒト体内での動態ならびに作... 観察研究 単一群 非盲検 \n",
"5 切除可能な後腹膜発生高リスク脱分化型脂肪肉腫および平滑筋肉腫を対象に、標準治療である根治的手... 介入研究 無作為化比較 非盲検 \n",
"6 転移・再発に対して標準治療がない又は不応若しくは不耐の EPHB4 受容体を発現するユーイン... NaN 単一群 非盲検 \n",
"7 皮膚血管肉腫のパクリタキセル単剤療法無効症例を対象にTM5614とパクリタキセルの併用時にお... NaN 単一群 非盲検 \n",
"8 肉眼的根治切除をし得た後腹膜脱分化型脂肪肉腫患者の術前ドキソルビシン・イホスファミド療法の有... 介入研究 単一群 非盲検 \n",
"9 骨軟部肉腫に対して既存の重粒子線治療法の生物線量を維持しつつ、腫瘍内の線量平均LET値の最適... 介入研究 単一群 非盲検 \n",
"10 切除可能なStage IIIA/B（T2-4N0M0）の非円形細胞軟部肉腫を対象に、標準治療... 介入研究 無作為化比較 非盲検 \n",
"11 CAMPFIRE：ユーイング肉腫患者を対象としたアベマシクリブ（LY2835219)の研究 NaN 無作為化比較 非盲検 \n",
"12 臨床病期ⅡA、ⅡB、Ⅲ期、Ⅳ期又は術後再発の高悪性骨肉腫患者に対してファスジル＋MAP療法（... 介入研究 単一群 非盲検 \n",
"13 標準治療により不応・不耐もしくは再発又は進行HER2陽性骨・軟部肉腫および婦人科悪性腫瘍患者... NaN 単一群 非盲検 \n",
"14 HRD陽性再発・難治性婦人科希少がんに対するNiraparibの安全性・有効性を評価する。 NaN 単一群 非盲検 \n",
"15 Stage 2、3、Group IIIに分類される胎児型横紋筋肉腫、Group I, II、... 介入研究 単一群 非盲検 \n",
"16 Stage 1、 Group III（眼窩Group III N0、NXを除く）、または、S... 介入研究 単一群 非盲検 \n",
"17 新規に診断された限局性ユーイング肉腫ファミリー腫瘍（ESFT）に対して、VDC-IE療法を顆... 介入研究 単一群 非盲検 \n",
"18 本試験は、再発または遠隔転移を有する進行骨軟部肉腫に対するゲムシタビン/ドセタキセル併用療法... 介入研究 単一群 非盲検 \n",
"19 悪性骨軟部腫瘍に対する炭酸ガス経皮吸収の安全性と有用性を評価すること 介入研究 単一群 非盲検 \n",
"20 頭蓋底脊索腫術後に対する陽子線治療の有効性・安全性判定 介入研究 単一群 非盲検 \n",
"\n",
" 対照 割付け 研究目的 ... \\\n",
"0 非対照 単群比較 治療 ... \n",
"1 非対照 単群比較 治療 ... \n",
"2 ヒストリカルコントロール 単群比較 治療 ... \n",
"3 プラセボ対照 並行群間比較 治療 ... \n",
"4 非対照 単群比較 治療 ... \n",
"5 実薬（治療）対照 並行群間比較 治療 ... \n",
"6 非対照 単群比較 治療 ... \n",
"7 非対照 単群比較 治療 ... \n",
"8 非対照 単群比較 治療 ... \n",
"9 非対照 単群比較 治療 ... \n",
"10 実薬（治療）対照 並行群間比較 治療 ... \n",
"11 実薬（治療）対照 並行群間比較 治療 ... \n",
"12 非対照 単群比較 治療 ... \n",
"13 非対照 単群比較 治療 ... \n",
"14 非対照 単群比較 治療 ... \n",
"15 無治療対照/標準治療対照 単群比較 治療 ... \n",
"16 非対照 単群比較 治療 ... \n",
"17 非対照 単群比較 治療 ... \n",
"18 非対照 単群比較 治療 ... \n",
"19 非対照 単群比較 治療 ... \n",
"20 非対照 単群比較 治療 ... \n",
"\n",
" Inclusion Criteria \\\n",
"0 1. Diagnosed or suspected to have a non-treate... \n",
"1 1)\\tHistologically diagnosed with cutaneous an... \n",
"2 1. Patients with pathologically diagnosed mali... \n",
"3 Have a histopathological diagnosis (fresh or b... \n",
"4 1.Patients enrolled in CARTiEr study\\n\\r\\n2.Wr... \n",
"5 * Histologically proven primary high risk leio... \n",
"6 1.Patients who have voluntarily provided writt... \n",
"7 (1) Patients who are 18 years old over (at the... \n",
"8 The patients diagnosed with de-differentiated ... \n",
"9 1. Histologically diagnosed high-grade bone an... \n",
"10 (1) Grade 2 or 3 (FNCLCC histological grading ... \n",
"11 -Diagnosis of Ewing's sarcoma or Ewing's sarco... \n",
"12 1.\\tStage2A, 2B, 3,4, or recurrent high grade ... \n",
"13 SC1 (before apheresis)\\n\\r\\n1. Patients diagno... \n",
"14 Patients who meet all of the following criteri... \n",
"15 1) Histologically confirmed newly diagnosed rh... \n",
"16 1) Histologically confirmed newly diagnosed em... \n",
"17 1. Histologically confirmed newly diagnosed ES... \n",
"18 1)Patients are histopathologically diagnosed a... \n",
"19 (1) Patients who have been histologically diag... \n",
"20 1, Pathological diagnosis is chordoma or chond... \n",
"\n",
" Exclusion Criteria \\\n",
"0 If the research director or co-researchers det... \n",
"1 1)\\tPatients previously treated with anti-PD-1... \n",
"2 1. Patients who have received a cumulative dos... \n",
"3 Are unable to swallow oral medication.\\n\\r\\nPr... \n",
"4 1.Written consent has not been obtained from t... \n",
"5 * Sarcoma originating from bone structure, abd... \n",
"6 1.Patients with other malignancies or history ... \n",
"7 (1) Patients with concomitant or pre-existing ... \n",
"8 The patients have a severe allergy and drug hy... \n",
"9 1.\\tPatients with serious complications.\\n\\r\\n... \n",
"10 (1) Synchronous or metachronous (within 5 year... \n",
"11 -Participants with severe and/or uncontrolled ... \n",
"12 1.\\tLatest adequate organ function as proved b... \n",
"13 SC1 (pre-apheresis), SC2 (pre-treatment initia... \n",
"14 Subject will be excluded from the trial if the... \n",
"15 1) patients with synchronous or metachronous c... \n",
"16 1) patients with primary tumor of CNS origin, ... \n",
"17 1. Patients with synchronous or metachronous c... \n",
"18 1)Active double cancers within 5 years(cured i... \n",
"19 (1) Skin ulcer or pathological fracture in the... \n",
"20 1, Multiple primary cancers\\n\\r\\n2, Invasion f... \n",
"\n",
" Age Minimum Age Maximum Gender \\\n",
"0 No limit 40age old not \n",
"1 18age old over 85age old under Both \n",
"2 18age old exceed No limit Both \n",
"3 18age old over No limit Both \n",
"4 18age old over No limit Both \n",
"5 18age old over No limit Both \n",
"6 18age old over No limit Both \n",
"7 18age old over No limit Both \n",
"8 18age old over No limit Both \n",
"9 No limit No limit Both \n",
"10 16age old over 70age old under Both \n",
"11 1age old over 39age old under Both \n",
"12 14age old over 65age old not Both \n",
"13 5age old over 65age old not Both \n",
"14 20age old over No limit Female \n",
"15 1age old over 29age old under Both \n",
"16 No limit 29age old under Both \n",
"17 No limit 50age 0month old not Both \n",
"18 10age 0month 0week old over 70age 11month 4week old under Both \n",
"19 16age old over No limit Both \n",
"20 15age old over No limit Both \n",
"\n",
" Discontinuation Criteria \\\n",
"0 None \n",
"1 None \n",
"2 None \n",
"3 None \n",
"4 None \n",
"5 None \n",
"6 None \n",
"7 None \n",
"8 None \n",
"9 None \n",
"10 None \n",
"11 None \n",
"12 None \n",
"13 None \n",
"14 None \n",
"15 None \n",
"16 None \n",
"17 None \n",
"18 None \n",
"19 None \n",
"20 None \n",
"\n",
" Keyword \\\n",
"0 hepatoblastoma, HCN-NOS, hepatocellular carcin... \n",
"1 cutaneous angiosarcoma, angiosarcoma \n",
"2 Soft tissue sarcoma \n",
"3 Chondrosarcoma \n",
"4 \n",
"5 \n",
"6 \n",
"7 \n",
"8 retroperitoneal de-differentiated liposarcoma \n",
"9 sarcoma \n",
"10 \n",
"11 \n",
"12 \n",
"13 \n",
"14 gynecology, malignancy, rare, gynecologic rare... \n",
"15 Rhabdomyosarcoma \n",
"16 rhabdomyosarcoma \n",
"17 Ewing sarcoma \n",
"18 \n",
"19 sarcoma \n",
"20 proton radiation therapy, proton beam therapy,... \n",
"\n",
" Intervention(s) Phase \\\n",
"0 NaN \n",
"1 Each course is set at 21 days. Pembrolizumab 2... NaN \n",
"2 Doxorubicin (60 mg/m2) for 15 minutes, Trabect... NaN \n",
"3 Drug: Ivosidenib 500mg or Placebo\\n\\r\\nProvide... NaN \n",
"4 NaN \n",
"5 Patients in the standard arm (surgery alone) w... NaN \n",
"6 Administration of CAR-T cells produced from er... NaN \n",
"7 (TM5614)\\n\\r\\nTM5614 should be taken orally af... NaN \n",
"8 Doxorubicin (20mg/m2/day), IV, given on day1-3... NaN \n",
"9 Multi-ion radiotherapy NaN \n",
"10 Arm A: Three courses of preoperative chemother... NaN \n",
"11 -Drug: Abemaciclib\\n\\r\\n Orally\\n\\r\\n Ot... NaN \n",
"12 fasudil hydrochloride hydrate as an IV infusion NaN \n",
"13 Administration of CAR-T cells produced from er... NaN \n",
"14 A 200 mg dose of niraparib is orally administe... NaN \n",
"15 chemotherapy 43 weeks \\n\\r\\nVAC2.2 therapy 9 c... NaN \n",
"16 chemotherapy 43 weeks \\n\\r\\nVAC1.2 therapy 9 c... NaN \n",
"17 Chemotherapy\\n\\r\\nStandard therapy for localiz... NaN \n",
"18 Gemcitabine (900 mg/m2) intravenously(IV) on D... NaN \n",
"19 Transcutaneous carbon dioxide (CO2) applicatio... NaN \n",
"20 Proton Radiation Therapy NaN \n",
"\n",
" Target \n",
"0 初発の小児・AYA世代の肝悪性腫瘍（肝芽腫、HCN-NOS、肝細胞癌、肝内胆管癌、肝未分化肉... \n",
"1 切除不能皮膚血管肉腫 \n",
"2 軟部肉腫 \n",
"3 未治療又は1レジメンの全身治療歴を有するIDH1変異陽性の局所進行又は転移性の通常型軟骨肉腫 \n",
"4 標準治療がない又は不応若しくは不耐の進行再発と診断されたユーイング肉腫又は固形がん \n",
"5 後腹膜原発性高リスク脱分化型脂肪肉腫または平滑筋肉腫 \n",
"6 標準治療がない又は不応若しくは不耐の進行再発と診断されたユーイング肉腫又は固形がん \n",
"7 皮膚血管肉腫 \n",
"8 後腹膜脱分化型脂肪肉腫 \n",
"9 骨軟部肉腫 \n",
"10 切除可能高悪性度非円形細胞軟部肉腫 \n",
"11 ・肉腫、ユーイング 、・新生物転移 \n",
"12 高悪性骨肉腫 \n",
"13 標準治療不応・不耐もしくは再発又は進行HER2陽性骨・軟部肉腫および婦人科悪性腫瘍 \n",
"14 【コホートA】BRCA変異陽性の子宮平滑筋肉腫：募集中\\n【コホートB】BRCA変異陰性・H... \n",
"15 横紋筋肉腫 \n",
"16 横紋筋肉腫 \n",
"17 ユーイング肉腫ファミリー腫瘍 \n",
"18 進行骨軟部肉腫 \n",
"19 悪性骨軟部腫瘍（骨軟部肉腫） \n",
"20 頭蓋底脊索腫・軟骨肉腫 \n",
"\n",
"[21 rows x 36 columns]"
]
},
"execution_count": 10,
"metadata": {},
"output_type": "execute_result"
}
],
"source": [
"sorted_df"
]
},
{
"cell_type": "code",
"execution_count": 11,
"metadata": {},
"outputs": [],
"source": [
"sorted_df.to_csv('../JRCT20241129sarcoma.csv')"
]
},
{
"cell_type": "code",
"execution_count": null,
"metadata": {},
"outputs": [],
"source": []
}
],
"metadata": {
"kernelspec": {
"display_name": "gradio",
"language": "python",
"name": "python3"
},
"language_info": {
"codemirror_mode": {
"name": "ipython",
"version": 3
},
"file_extension": ".py",
"mimetype": "text/x-python",
"name": "python",
"nbconvert_exporter": "python",
"pygments_lexer": "ipython3",
"version": "3.12.3"
}
},
"nbformat": 4,
"nbformat_minor": 2
}
|